Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer
Ryohei Nishino(The University of Tokyo), Yataro Daigo(The University of Tokyo), Hiroyuki Ito(Kanagawa Prefectural Hospital Organization), Eiju Tsuchiya(Kanagawa Prefectural Hospital Organization), Yohei Miyagi(Kanagawa Cancer Center), Hirohiko Akiyama(Hiroshima University), Nobuhisa Ishikawa(The University of Tokyo), Atsushi Takano(The University of Tokyo), Yusuke Nakamura(Rissho University), Haruhiko Nakayama, Nobuoki Kohno(Hiroshima University), Hideto Oshita(Hiroshima University)
Cited by 76
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy
|Nature|1998|804